Hims Review 2026
Reviewed August 7, 2026 · Brand-name FDA-approved for new patients — Wegovy injectable, Wegovy pill and Zepbound. Compounded semaglutide was discontinued for new patients in March 2026.
Visit Hims WebsiteOverview
Hims is one of the largest direct-to-consumer telehealth platforms in the US and part of a publicly traded company, and its weight-loss offering changed fundamentally in 2026. Following a settlement with Novo Nordisk on 9 March 2026, Hims exited compounded semaglutide for new patients and moved to a brand-name model. That is the single most important fact about this provider now, and it is a change for the better on safety: where the platform previously sold compounded semaglutide at $99 and briefly $49 a month, new patients are now prescribed FDA-approved medication — injectable Wegovy at a reported $299/month, the oral Wegovy pill at $249/month, or Zepbound at $399/month. Those products have been evaluated by the FDA for safety, efficacy and quality; the compounded versions they replaced had not. The commercial structure is the familiar one, and the familiar trap: the $39 you see advertised is a first-month membership fee, it auto-renews at a reported $149/month, and medication is billed separately on top. Where Hims becomes genuinely competitive is with insurance — reported out-of-pocket costs fall to $0-$25/month with commercial coverage and Novo Nordisk copay assistance, which no compounded provider in this directory can match. One caveat on this review specifically: hims.com blocked automated access when we checked on 7 August 2026, so the figures above come from third-party reporting rather than from the company's own pages. We would normally verify at source and could not here.
Medications Offered
Brand-name or compounded: Brand-name FDA-approved for new patients — Wegovy injectable, Wegovy pill and Zepbound. Compounded semaglutide was discontinued for new patients in March 2026.
- Wegovy® injectable (semaglutide) — reported $299/month
- Wegovy® oral pill (semaglutide) — reported $249/month
- Zepbound® injectable (tirzepatide) — reported $399/month
- With commercial insurance and Novo Nordisk copay assistance, reported cost can fall to $0-$25/month
- Compounded semaglutide discontinued for new patients from March 2026
- Sister brand Hers offers a parallel service, with compounded semaglutide limited to cases of medical necessity
Consultation Process
Join for $39
The advertised $39 is the first month of membership. It does not include medication.
Online assessment and provider review
A licensed provider reviews your intake and determines whether a prescription is appropriate.
Insurance and copay assistance
This is the step that decides your real cost. Because the medication is brand-name, it can be billed to a pharmacy benefit, and Novo Nordisk copay assistance may apply — together these can bring out-of-pocket cost to a reported $0-$25/month.
Membership renews at ~$149/month
After the introductory month, membership renews at a reported $149/month, with medication charged separately unless covered.
Eligibility
- Adults; provider determines appropriateness after an online assessment
- Brand-name GLP-1 eligibility also follows the FDA-approved indication — BMI 30+, or 27+ with a weight-related comorbidity
- Where insurance is used, the insurer's prior-authorisation criteria also apply
- Standard GLP-1 contraindications apply
- US only; state coverage not verified in the sources available to us
Provider Involvement
Licensed providers assess and prescribe through the platform, with ongoing support delivered in-app. Hims has one of the more mature digital experiences in this market, built over years and at substantial scale. We were not able to verify the current check-in cadence or monitoring protocol from the company's own pages.
Lab Requirements
Not verified. Where insurance is involved, the insurer's prior-authorisation criteria typically drive required documentation.
Pharmacy Fulfillment
Brand-name manufacturer product. Since the March 2026 move away from compounded semaglutide for new patients, the 503A/503B compounding question that dominates the rest of this directory largely does not apply to new Hims patients — a meaningful simplification of the risk picture.
Shipping Frequency
Medication shipped to your door. Timing not verified in the sources available to us.
Membership Fees vs. Medication Fees
Membership fees
A reported $39 for the first month, auto-renewing at a reported $149/month. This is a membership fee and does not include GLP-1 medication.
Medication fees
- Membership: $39 first month, then a reported $149/month
- Wegovy injectable: reported $299/month
- Wegovy oral pill: reported $249/month
- Zepbound: reported $399/month
- With commercial insurance and copay assistance: reported $0-$25/month
Cancellation & Refund Policy
Cancellation
Not verified from source. Given the auto-renewing membership at a reported $149/month, confirm the cancellation process and any notice period before enrolling, and diarise your renewal date.
Refunds
Not verified from source. Confirm directly.
Insurance
This is now the strongest reason to use Hims. Because it prescribes brand-name FDA-approved medication, prescriptions can be billed to a pharmacy benefit and Novo Nordisk copay assistance may apply — reported to bring out-of-pocket cost down to $0-$25/month for insured patients. No compounded provider in this directory can offer anything comparable, because compounded products cannot be billed to a pharmacy benefit at all.
HSA / FSA
Not verified. Confirm directly.
See our GLP-1 insurance and HSA/FSA guide for how reimbursement works in practice.
Support Services
- In-app provider messaging and ongoing support
- Insurance and copay assistance navigation
- Mature mobile app and tracking experience
- Medication delivered to your door
State Availability
Not verified in the sources available to us.
Pros
- Exited compounded semaglutide for new patients in March 2026 — now brand-name only
- Offers injectable Wegovy, the oral Wegovy pill and Zepbound, all FDA-approved
- With commercial insurance and Novo Nordisk copay assistance, reported monthly cost can fall to $0-$25
- Publicly traded operator with audited financials and disclosure obligations
- Established platform with substantial scale and a mature app experience
- Oral Wegovy at a reported $249/month is among the cheaper brand-name oral routes
Cons
- Medication cost is separate from membership — the $39 is an introductory membership fee only
- Membership auto-renews at a reported $149/month after the first month
- Without insurance, medication at $249-$399/month sits on top of that membership
- The cheap compounded era is over — patients who joined for $99 semaglutide will pay considerably more
- Availability of any remaining compounded route is limited and not guaranteed
- Our figures come from third-party reporting; hims.com blocked direct verification at the time of checking
Who Hims May Be Best For
- Patients with commercial insurance, where copay assistance can make this the cheapest route in this directory
- Anyone who wants FDA-approved medication rather than compounded product
- People who want an oral brand-name option
Limitations
- Membership renews at a reported $149/month with medication charged separately
- Expensive without insurance coverage
- The cheap compounded option is no longer available to new patients
- Pricing could not be verified at source because the site blocked access
Reputation & Trust
The 2026 change reframes this provider entirely, and in the patient's favour. Hims settled with Novo Nordisk on 9 March 2026 and stopped offering compounded semaglutide to new patients, moving to FDA-approved brand-name medication. Whatever the commercial reasoning, the practical effect is that new Hims patients receive product that has been evaluated by the FDA for safety, efficacy and quality — which cannot be said of the compounded semaglutide the platform previously sold at $99 and briefly $49 a month, nor of most of the cheaper providers in this directory. Hims is also part of a publicly traded company, carrying audited financials and disclosure obligations that essentially no other provider reviewed here has. The reservations are commercial rather than clinical: a $39 introductory membership that renews at a reported $149/month with medication billed separately is the same structure that drives the largest complaint volumes elsewhere in this market, and patients who joined for cheap compounded semaglutide are now facing a materially higher bill. We should also be explicit that hims.com blocked our automated access on 7 August 2026, so unlike most reviews on this site the pricing here is third-party reported rather than verified at source. Treat the figures as indicative and confirm before enrolling.
What Makes Hims Different
- Brand-name FDA-approved medication only for new patients since March 2026
- Insurance plus manufacturer copay assistance can reduce cost to a reported $0-$25/month
- Oral Wegovy pill available as well as injectables
- Publicly traded operator with audited financials
- Mature app and support experience at scale
Our Verdict
Hims earns 4/5, and the reason has changed since our previous review. In March 2026 it settled with Novo Nordisk and exited compounded semaglutide for new patients, moving to FDA-approved brand-name medication — injectable Wegovy, the oral Wegovy pill and Zepbound. That removes at a stroke the central risk running through most of this directory: unapproved compounded product from unnamed pharmacies. Combined with a publicly traded parent carrying audited financials, a mature platform at real scale, and a route to insurance plus Novo Nordisk copay assistance that can reportedly bring out-of-pocket cost to $0-$25 a month, this is now one of the better options here for an insured patient. The trade-offs are honest ones. Uninsured patients who came for $99 compounded semaglutide will pay considerably more, since medication now runs $249-$399 a month on top of a membership that starts at $39 and renews at a reported $149. And this review carries a caveat we do not usually have to give: hims.com blocked our automated access, so the pricing here is third-party reported rather than verified at source. Confirm the numbers with Hims before enrolling — but if you have coverage, this belongs on your shortlist.
Alternatives to Hims
Also brand-name only with an insurance coordinator, at a lower $74/month membership.
The closest direct comparison — brand-name only with prior-authorisation support at a similar membership cost.
Brand-name only with published eligibility criteria and a $39 care fee rather than a recurring $149.
The sister brand, with a parallel weight-loss service aimed at women.
Compare more options on our best online GLP-1 providers and cheapest GLP-1 programs pages.
Frequently Asked Questions
Does Hims still offer $99 compounded semaglutide?
No, not for new patients. Hims settled with Novo Nordisk on 9 March 2026 and exited compounded semaglutide, moving to a brand-name model. The $99 — and briefly $49 — compounded era is over. New patients are prescribed FDA-approved Wegovy or Zepbound instead, at reported prices of $249 to $399 a month before insurance.
Is that change good or bad for patients?
On safety, good. Compounded semaglutide is not FDA-approved and has not been evaluated for safety, efficacy or quality; brand-name Wegovy and Zepbound have. On cost, worse for uninsured patients, who now face $249-$399 medication plus a membership rather than $99 all in. For insured patients it is better in both respects, because brand-name medication can be billed to a pharmacy benefit and compounded product cannot.
What will Hims actually cost me?
It depends entirely on insurance. Reported pricing is $39 for the first month of membership, renewing at $149/month, with medication separate at $299 for injectable Wegovy, $249 for the Wegovy pill or $399 for Zepbound. With commercial insurance and Novo Nordisk copay assistance, reported out-of-pocket cost can fall to $0-$25/month. Note that we could not verify these figures on hims.com directly — confirm before enrolling.
Does the $39 include medication?
No. It is a first-month membership fee. Medication is billed separately, and the membership renews at a reported $149/month afterwards. This is the same structure that generates most complaints against comparable platforms, so diarise your renewal date.
Important Notes & Warnings
- This review is informational only and is not medical advice. Consult a licensed clinician before starting or changing treatment.
- PRICING NOT VERIFIED AT SOURCE: hims.com blocked automated access when we checked on 7 August 2026. The figures in this review come from third-party reporting. Confirm current pricing directly with Hims before enrolling.
- The advertised $39 is a first-month membership fee and does NOT include medication. Membership renews at a reported $149/month.
- Hims exited compounded semaglutide for new patients in March 2026. If you are seeking the previous $99 compounded pricing, it is no longer available.
- GLP-1 medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2, and in pregnancy.
- Common side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain; serious risks include pancreatitis, gallbladder disease and kidney injury from dehydration.
- Brand-name GLP-1s are FDA-approved for adults with BMI 30 or above, or 27 or above with at least one weight-related condition.
Sources
- Third-party reporting on the Hims and Novo Nordisk settlement of 9 March 2026 and the resulting brand-name-only model and pricing (hims.com blocked automated access on 7 August 2026, so figures are not verified at source)
- FDA-approved indications for Wegovy (semaglutide) and Zepbound (tirzepatide) for chronic weight management
Medical Disclaimer
This review is for informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. GLP-1 medications are prescription drugs with real risks and contraindications. Only a licensed clinician who has evaluated you can decide whether any medication is appropriate. Talk to a healthcare provider before starting, changing, or stopping any treatment, and call emergency services for urgent symptoms.
Facts in this review were compiled from the provider's own public website and public search results as of August 7, 2026. Prices, medication availability, pharmacy partners, and policies change frequently and vary by state — verify everything directly with the provider before purchasing.
This page contains affiliate links. We may earn a commission from qualifying purchases at no additional cost to you.